Plasma Nicotine Levels Produced by Chewing Nicotine Gum
Abstract
Nicotine chewing gum is designed to maintain plasma nicotine levels during a smoking cessation effort while the individual copes with the loss of the repetitive behavioral components of smoking. The plasma nicotine levels obtained with hourly gum chewing were compared with levels obtained with cigarette smoking in nine patients with lung disease. Chewing 2- and 4-mg nicotine gum hourly produced mean steady-state plasma nicotine levels of 11.8 and 23.2 ng/mL, respectively. This compares with a mean plasma nicotine trough level during usual smoking of 15.7 ng/mL and a mean trough level of 18.3 ng/mL with hourly smoking of a cigarette with a nicotine yield of 1.1 mg. Few side effects were seen with the use of either the 2- or 4-mg gum. In a short-term study, nicotine gum proved an acceptable source of nicotine for aiding smoking cessation.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Medically approved oral smoking cessation aids such as nicotine gum and nicotine lozenges with a higher nicotine content and which give greater nicotine delivery to users have previously been shown to be more effective in assisting smoking cessation than products with a lower nicotine content, particularly in more heavily dependent smokers.
“medically approved oral smoking cessation aids such as nicotine gum and nicotine lozenges with a higher nicotine content and which give greater nicotine delivery to users [36] have previously been shown to be more effective in assisting smoking cessation than products with a lower nicotine content, particularly in more heavily dependent smokers [37–40].”
From A Randomised Study to Investigate the Nicotine Pharmacokinetics of Oral Nicotine Pouches and a Combustible Cigarette (2022) · cites this paper as [36]
Cited by
Sorted by citations
Effects of Nicotine During Pregnancy: Human and Experimental Evidence
Wickstrom, R. (2007) · Current Neuropharmacology · doi:10.2174/157015907781695955 · Cited by 256 · see citing works
McEwan, M., Azzopardi, D., Gale, N., Camacho, O. M., Hardie, G., Fearon, I. M., & Murphy, J. (2022) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-021-00742-9 · Cited by 70 · see citing works
- Authors
- McNabb, M. E.
- Venue
- JAMA: The Journal of the American Medical Association
- Publisher
- American Medical Association (AMA)
- Published
- 1982-08-20
- Volume
- 248
- Issue
- 7
- Pages
- 865
- ISSN
- 0098-7484
- Cited by
- 63
- References
- 0
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
